These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 17938129

  • 21. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M, Ocampo A, Aguirrebengoa K, Cervantes M, Pascual A, Echeverria S, Asensi V, Barreiro P, Garcia-Samaniego J, Soriano V, PRESCO Team.
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.
    Merchante N, de los Santos-Gil I, Merino D, González-Serrano M, Mira JA, Sanz-Sanz J, Fernández-Fuertes E, Ruiz-Morales J, del Valle J, Macías J, Moro A, Pineda JA.
    J Hepatol; 2009 Apr; 50(4):684-92. PubMed ID: 19231001
    [Abstract] [Full Text] [Related]

  • 25. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005 Apr; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 26. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
    Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA, Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas.
    Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
    [Abstract] [Full Text] [Related]

  • 27. Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
    Hepatitis C- working group for COHERE in Eurocoord, Smit C, Arends J, Peters L, Montforte Ad, Dabis F, Zangerle R, Daikos G, Mussini C, Mallolas J, de Wit S, Zinkernagel A, Cosin J, Chene G, Raben D, Rockstroh J.
    BMC Infect Dis; 2015 Nov 04; 15():498. PubMed ID: 26537918
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.
    Ann Hepatol; 2013 Nov 04; 12(2):228-35. PubMed ID: 23396734
    [Abstract] [Full Text] [Related]

  • 31. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
    Antivir Ther; 2008 Nov 04; 13(4):511-7. PubMed ID: 18672529
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
    Dore GJ, Torriani FJ, Rodriguez-Torres M, Bräu N, Sulkowski M, Lamoglia RS, Tural C, Clumeck N, Nelson MR, Mendes-Correa MC, Godofsky EW, Dieterich DT, Yetzer E, Lissen E, Cooper DA.
    AIDS; 2007 Jul 31; 21(12):1555-9. PubMed ID: 17630550
    [Abstract] [Full Text] [Related]

  • 35. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
    Avidan NU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, Buti M, Fauci AS, Polis MA, Kottilil S.
    J Acquir Immune Defic Syndr; 2009 Dec 01; 52(4):452-8. PubMed ID: 19797971
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.
    J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):174-8. PubMed ID: 17106276
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.